Citadel Advisors
ELTX icon

Citadel Advisors’s Elicio Therapeutics ELTX Stock Holding History

Citadel Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$484K Buy
45,300
+10,100
+29% +$97.5K ﹤0.01% 9392
2025
Q4 		$280K Buy
35,200
+14,200
+68% +$129K ﹤0.01% 10285
2025
Q3 		$230K Buy
+21,000
New +$213K ﹤0.01% 10945

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's ELTX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 15,978 shares worth $171K. The stake represents ﹤0.01% of the portfolio and ranks #11569 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ELTX as recently as Q3 2024.

Citadel Advisors first reported a position in ELTX in Q1 2021 and has held it in 8 quarters since. The position peaked at $631K in Q1 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Citadel Advisors held 15,978 shares of Elicio Therapeutics worth $171K as of Q1 2026.
  • Elicio Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Elicio Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11569 holding.
  • Citadel Advisors first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • Citadel Advisors's Elicio Therapeutics position peaked at $631K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.